

**Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4)
Recombinant Antibody
Catalog # APR10872****Specification**

Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P02776
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	144.5 KDa

Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Additional Information**Target/Specificity**

CXCL4 / PF4

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Protein Information**Name** PF4**Synonyms** CXCL4, SCYB4**Function**

Chemokine released during platelet aggregation that plays a role in different biological processes including hematopoiesis, cell proliferation, differentiation, and activation (PubMed:29930254, PubMed:9531587). Acts via different functional receptors including CCR1, CXCR3A or CXCR3B (PubMed:18174362, PubMed:29930254). Upon interaction with CXCR3A receptor, induces activated T-lymphocytes migration mediated via downstream Ras/extracellular signal-regulated kinase (ERK) signaling (PubMed:18174362, PubMed:18174362).

href="http://www.uniprot.org/citations/24469069" target="_blank">24469069). Neutralizes the anticoagulant effect of heparin by binding more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Plays a role in the inhibition of hematopoiesis and in the maintenance of hematopoietic stem cell (HSC) quiescence (PubMed:9531587). Chemotactic for neutrophils and monocytes via CCR1 (PubMed:29930254). Inhibits endothelial cell proliferation. In cooperation with toll-like receptor 8/TLR8, induces chromatin remodeling and activates inflammatory gene expression via the TBK1-IRF5 axis (PubMed:35701499). In addition, induces myofibroblast differentiation and collagen synthesis in different precursor cells, including endothelial cells, by stimulating endothelial-to-mesenchymal transition (PubMed:34986347). Interacts with thrombomodulin/THBD to enhance the activation of protein C and thus potentiates its anticoagulant activity (PubMed:9395524).

Cellular Location


Secreted.

Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Images



Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) is more than 95%, determined by SEC-HPLC.